FDA notifications.  Tentative approval given for combination of abacavir, lamivudine & zidovudine tablets.
D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000627:therapeutic use*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D013607:Tablets; D014481:United States; D014486:United States Food and Drug Administration; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use*; D000099227:Abacavir
D015224:Dideoxynucleosides; D019259:Lamivudine; D018894:Reverse Transcriptase Inhibitors; D013607:Tablets; D015215:Zidovudine; D000099227:Abacavir